{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:50:56Z","timestamp":1786121456291,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Older adults hospitalized with community-acquired pneumonia (CAP) often recover slowly despite standard care. Chaihu Guizhi Tang combined with Maxing Shigan Tang (CHGZ + MXSG) is used as adjunctive traditional Chinese medicine for respiratory infections, but prospective evidence in older inpatients is limited. We evaluated its association with short-term clinical recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this open-label prospective non-randomized controlled study, 186 older adults hospitalized with CAP received adjunctive CHGZ + MXSG plus standard care (\n                      <jats:italic>n<\/jats:italic>\n                      = 93) or standard care alone (\n                      <jats:italic>n<\/jats:italic>\n                      = 93) after eligibility confirmation, clinical assessment, and clinician-patient discussion. The primary outcome was day-7 clinical cure. Secondary outcomes included 72-h clinical response, time to clinical stability, antibiotic escalation, treatment failure, length of stay, CRP and symptom-score changes, 28-day readmission and mortality, and prespecified treatment-emergent safety events. Multivariable, expanded covariate-adjusted, propensity-score weighting\/matching, and follow-up sensitivity analyses were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Day-7 clinical cure occurred in 74 of 93 participants (79.6%) in the CHGZ + MXSG group and 58 of 93 participants (62.4%) in the standard-care group [unadjusted risk ratio 1.28, 95% confidence interval (CI) 1.06 to 1.54;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.010). The CHGZ + MXSG group also had earlier clinical response at 72 h, less antibiotic escalation, shorter mean time to clinical stability, shorter hospital stay, greater CRP reduction by day 5, and greater symptom-score reduction by day 7. In the multivariable-adjusted model, CHGZ + MXSG was associated with higher odds of day-7 clinical cure [odds ratio (OR) 2.37, 95% CI 1.18\u20134.90], earlier clinical stability [hazard ratio (HR) 1.73, 95% CI 1.27\u20132.35], and shorter hospital stay (beta \u22120.99 days, 95% CI \u22121.49 to \u22120.49). These findings were directionally consistent across expanded covariate-adjusted analyses, stabilized inverse probability of treatment weighting, trimmed weighting, overlap weighting, 1:1 propensity-score matching, and follow-up sensitivity analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among hospitalized older adults with CAP, adjunctive CHGZ + MXSG plus standard care was associated with faster short-term clinical recovery and no descriptive excess of the prespecified safety events. Because treatment allocation was not randomized and outcome assessment was open-label, these findings should be interpreted as adjusted associations rather than definitive causal effects and should be evaluated in adequately powered randomized or pragmatic trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1880550","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:29:24Z","timestamp":1786080564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive Chaihu Guizhi Tang combined with Maxing Shigan Tang and short-term clinical recovery in hospitalized older adults with community-acquired pneumonia: a prospective non-randomized controlled study"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhaolong","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Traditional Chinese Medicine, The Thirteenth People\u2019s Hospital of Chongqing\/ Chongqing Geriatrics Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, The Thirteenth People\u2019s Hospital of Chongqing\/ Chongqing Geriatrics Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, The Thirteenth People\u2019s Hospital of Chongqing\/ Chongqing Geriatrics Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, The Thirteenth People\u2019s Hospital of Chongqing\/ Chongqing Geriatrics Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, The Thirteenth People\u2019s Hospital of Chongqing\/ Chongqing Geriatrics Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America.","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2200735","DOI":"10.1183\/13993003.00735-2022","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia.","volume":"61","author":"Martin-Loeches","year":"2023","journal-title":"Eur Respir J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"18","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2217\/ahe.09.74","article-title":"Community-acquired pneumonia in elderly patients.","volume":"5","author":"Stupka","year":"2009","journal-title":"Aging health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"190126","DOI":"10.1183\/16000617.0126-2019","article-title":"Community-acquired pneumonia in critically ill very old patients: a growing problem.","volume":"29","author":"Cill\u00f3niz","year":"2020","journal-title":"Eur Respir Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S1473-3099(24)00176-2","article-title":"Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.","volume":"24","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia.","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","article-title":"Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.","volume":"58","author":"Lim","year":"2003","journal-title":"Thorax"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.279.18.1452","article-title":"Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines.","volume":"279","author":"Halm","year":"1998","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1086\/426028","article-title":"Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients.","volume":"39","author":"Men\u00e9ndez","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/1469-0691.12173","article-title":"An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia.","volume":"19","author":"Akram","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1378\/chest.108.5.1288","article-title":"C-reactive protein. A clinical marker in community-acquired pneumonia.","volume":"108","author":"Smith","year":"1995","journal-title":"Chest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/thx.2007.086785","article-title":"Markers of treatment failure in hospitalised community acquired pneumonia.","volume":"63","author":"Men\u00e9ndez","year":"2008","journal-title":"Thorax"},{"key":"B14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.amjmed.2007.10.033","article-title":"C-reactive protein is an independent predictor of severity in community-acquired pneumonia.","volume":"121","author":"Chalmers","year":"2008","journal-title":"Am J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.88","article-title":"Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.","volume":"313","author":"Torres","year":"2015","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia.","volume":"388","author":"Dequin","year":"2023","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"106919","DOI":"10.1016\/j.phrs.2023.106919","article-title":"Guideline on treating community-acquired pneumonia with Chinese patent medicines.","volume":"196","author":"Wang","year":"2023","journal-title":"Pharmacol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.19540\/j.cnki.cjcmm.20200714.501","article-title":"[Systematic review of randomized controlled trial of Maxing Shigan Decoction in treatment of community acquired pneumonia].","volume":"46","author":"Li","year":"2021","journal-title":"Zhongguo Zhong Yao Za Zhi ."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1639027","DOI":"10.3389\/fmed.2025.1639027","article-title":"Effectiveness and safety of Maxing Shigan Decoction for community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials.","volume":"12","author":"Ling","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"948831","DOI":"10.3389\/fphar.2022.948831","article-title":"Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: a randomized, double-blind, placebo-controlled, multicenter trial.","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2105\/ajph.94.3.361","article-title":"Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement.","volume":"94","author":"Des Jarlais","year":"2004","journal-title":"Am J Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","article-title":"Addressing extreme propensity scores via the overlap weights.","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial.","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1183\/09031936.00003608","article-title":"Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia.","volume":"32","author":"Bruns","year":"2008","journal-title":"Eur Respir J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/j.1469-0691.2009.02856.x","article-title":"Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia.","volume":"15","author":"Hohenthal","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"B30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.7326\/M15-0715","article-title":"Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis.","volume":"163","author":"Siemieniuk","year":"2015","journal-title":"Ann Intern Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/cid\/cix801","article-title":"Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis.","volume":"66","author":"Briel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12877-023-04029-3","article-title":"Prognostic significance of frailty in hospitalized elderly patients with community-acquired pneumonia: a retrospective cohort study.","volume":"23","author":"Zhao","year":"2023","journal-title":"BMC Geriatr"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1880550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:29:25Z","timestamp":1786080565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1880550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":32,"alternative-id":["10.3389\/fmed.2026.1880550"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1880550","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"article-number":"1880550"}}